Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway

Background: Autologous hematopoietic stem cell transplantation (HSCT) is a potent treatment option for patients with aggressive relapsing-remitting multiple sclerosis (RRMS). Objective: To evaluate long-term outcomes of HSCT in MS. Methods: National retrospective single-center observational study of...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis 2024-05, Vol.30 (6), p.751-754
Main Authors: Kvistad, Christopher Elnan, Lehmann, Anne Kristine, Kvistad, Silje Agnethe Stokke, Holmøy, Trygve, Lorentzen, Åslaug Rudjord, Trovik, Linn Hereide, Kristoffersen, Einar Klæboe, Bø, Lars, Torkildsen, Øivind
Format: Article
Language:English
Subjects:
Adult
Autografts
Disease Progression
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Humans
Magnetic resonance imaging
Male
Middle Aged
Multiple sclerosis
Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging
Multiple Sclerosis, Relapsing-Remitting - therapy
Norway
Patients
Retrospective Studies
Short Reports
Stem cell transplantation
Transplantation, Autologous
Treatment Outcome
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Autologous hematopoietic stem cell transplantation (HSCT) is a potent treatment option for patients with aggressive relapsing-remitting multiple sclerosis (RRMS). Objective: To evaluate long-term outcomes of HSCT in MS. Methods: National retrospective single-center observational study of patients with aggressive RRMS that underwent HSCT in Norway from January 2015 to January 2018. Criteria for receiving HSCT included at least two clinical relapses the last year while on disease modifying treatment (DMT). Results: In total, 29 patients, with a mean follow-up time of 70 months (standard deviation:14.3), were evaluated. Twenty patients (69%) had sustained no evidence of disease activity (NEDA-3) status, 24 (83%) were relapse-free, 23 (79%) free of magnetic resonance imaging (MRI) activity, and 26 (90%) free of progression. Number of patients working full-time increased from 1 (3%), before HSCT, to 10 (33%) after 2 years and 15 (52%) after 5 years. Conclusion: HSCT offers long-term disease-free survival with successively increasing work participation in patients with aggressive MS resistant to DMTs.
ISSN:1352-4585
1477-0970
DOI:10.1177/13524585241231665